Know Cancer

forgot password

Unrelated Umbilical Cord Blood As An Alternate Source Of Stem Cells Transplantation

Phase 2
17 Years
Not Enrolling
Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases

Thank you

Trial Information

Unrelated Umbilical Cord Blood As An Alternate Source Of Stem Cells Transplantation


- Determine 180-day survival in patients with malignant or nonmalignant hematologic
diseases treated with allogeneic umbilical cord blood transplantation. (Severe aplastic
anemia, Fanconi anemia, and marrow failure syndromes strata are closed to accrual;
adult [over 18 years of age] patient stratum is closed to accrual.)

- Determine disease-free and long-term survival in patients treated with this regimen.

- Determine the incidence of neutrophil engraftment, primary and secondary graft failure,
platelet engraftment, and red blood cell engraftment in patients treated with this

- Determine the incidence and severity of acute and chronic graft-versus-host disease in
patients treated with this regimen.

- Determine the incidence of complications, including infection, veno-occlusive disease,
and interstitial pneumonitis, in patients treated with this regimen.

- Determine the incidence of relapse, other malignancies, lymphoproliferative disorders,
and posttransplantation myelodysplasia in patients treated with this regimen.

- Determine the immune reconstitution in patients treated with this regimen.

OUTLINE: This is a multicenter study. Patients are grouped according to the following

- Stratum I: Malignant disease, 5/6 or 6/6 HLA match, age 18 and under

- Stratum II: Malignant disease, 4/6 HLA match, age 18 and under

- Stratum III: Malignant disease, 3/6 HLA match, age 18 and under

- Stratum IV: Malignant disease, 2/6 or 1/6 HLA match, age 18 and under

- Stratum V (closed to accrual): Severe aplastic anemia, Fanconi anemia, or other marrow
failure syndrome

- Stratum VI: Inborn errors of metabolism/storage diseases and other nonmalignant
diseases not included in stratum V

- Stratum VII: Malignant disease receiving alternative conditioning regimen comprising
busulfan and melphalan

- Stratum VIII (closed to accrual): Adult patients (over age 18)

- Conditioning therapy: Patients are assigned to 1 of 5 groups according to diagnosis.

- Group I (malignant disease or severe aplastic anemia [severe aplastic anemia
closed to accrual]): Patients undergo total body irradiation (TBI) once or twice
daily on days -8 to -4. Patients then receive cyclophosphamide IV on days -3 and
-2, methylprednisolone IV on days -3 to 0, and antithymocyte globulin (ATG) IV
once or twice daily on days -3 to -1.

- Group II (Fanconi anemia [closed to accrual]): Patients undergo TBI on day -6, and
then receive cyclophosphamide IV and fludarabine IV on days -5 to -2, and
methylprednisolone IV and ATG IV on days -5 to -1.

- Group III (inborn errors of metabolism/storage disease): Patients receive oral
busulfan 4 times daily on days -9 to -6, cyclophosphamide as in group II, and
methylprednisolone and ATG as in group I.

- Group IV (other nonmalignant diseases): Patients receive conditioning therapy as
in group III. Patients with familial erythrophagocytic lymphohistiocytosis or
Langerhans cell histiocytosis also receive etoposide on days -5 to -3.

- Group V (non-TBI regimen for leukemia patients under 2 years of age): Patients
receive oral busulfan 4 times daily on days -8 to -5, melphalan IV on days -4 to
-2, and methylprednisolone and ATG as in group I.

- Allogeneic umbilical cord blood transplantation: All patients undergo umbilical cord
blood transplantation on day 0. Beginning on day 0 or 1, patients receive filgrastim
(G-CSF) IV or subcutaneously daily until blood counts recover.

- Graft-versus-host disease prophylaxis: Patients receive cyclosporine (IV or oral)
beginning between days -3 and -1 and continuing for 1 year after transplantation and
methylprednisolone twice daily beginning on day 1 and continuing until blood counts

Patients are followed weekly for 14 weeks, at 100 days, and at 4, 5, 6, 9, 12, 18, 24, and
36 months.

PROJECTED ACCRUAL: A total of 360 patients will be accrued for this study.

Inclusion Criteria


- Diagnosis of 1 of the following hematologic malignancies:

- Acute myeloid leukemia (AML)*

- With or without history of myelodysplastic syndromes (MDS)

- Patients in first complete remission (CR) (no greater than 5% blasts in
marrow) with translocations t(8;21) and inv(16) are allowed provided they
failed first-line induction therapy

- Patients in first CR (no greater than 5% blasts in marrow) with
translocations t(15;17) are allowed provided at least 1 of the following is

- Failed first-line induction therapy

- Molecular evidence of persistent disease

- No patients in first CR and with Down syndrome

- Acute lymphoblastic leukemia (ALL)*, meeting 1 of the following criteria:

- Not in first CR (no greater than 5% blasts in marrow)

- In first CR and high risk as defined by 1 of the following:

- Hypoploidy (no more than 44 chromosomes)

- Pseudodiploidy with translocations or molecular evidence of t(9;22),
11q23, or t(8;14) (excluding B-ALL) or +MLL gene rearrangement

- One of the following elevated WBC levels:

- WBC greater than 100,000/mm^3 if 6 to 12 months of age

- WBC greater than 200,000/mm^3 if between 10 and 17 years of age

- WBC greater than 20,000/mm^3 if 18 years of age and over (adult
[over 18 years of age] patient stratum closed to accrual)

- Failed to achieve CR after 4 weeks of induction therapy

- B-ALL that is not in first CR or that meets at least 1 of the high-risk
criteria specified above

- No translocation t(8;14)

- No blasts with surface immunoglobulins

- CD10 negative

- Undifferentiated leukemia*

- Infant leukemia*

- Biphenotypic leukemia*

- Chronic myelogenous leukemia, meeting 1 of the following criteria:

- Accelerated phase

- Chronic phase

- At least 1 year from diagnosis without an identified matched unrelated
bone marrow donor AND unresponsive to or unable to tolerate interferon

- Blast crisis* (greater than 30% promyelocytes plus blasts in the marrow)

- One of the following MDS:

- Refractory anemia

- Refractory anemia with ringed sideroblasts

- Refractory anemia with excess blasts (RAEB)

- RAEB in transformation

- Chronic myelomonocytic leukemia

- Paroxysmal nocturnal hemoglobinuria

- Hodgkin's or non-Hodgkin's lymphoma beyond first CR or failed primary induction

- Tumor displays chemosensitivity (greater than 50% reduction in mass size
after the most recent therapy) NOTE: *Patients in third or greater
medullary relapse or refractory disease (other than primary induction
failures) or blast crisis receive the study busulfan/melphalan conditioning


- Diagnosis of one of the following nonmalignant diseases :

- Acquired severe aplastic anemia (stratum closed to accrual)

- Unresponsive to medical therapy with anti-thymocyte globulin and/or

- Inborn errors of metabolism, including, but not limited to the following:

- Hurler's syndrome

- Adrenoleukodystrophy

- Maroteaux-Lamy syndrome

- Globoid cell leukodystrophy

- Metachromatic leukodystrophy

- Fucosidosis

- Mannosidosis

- Fanconi anemia documented by increased chromosomal fragility assays and meeting
1 of the following criteria (stratum closed to accrual):

- Severe pancytopenia

- Absolute neutrophil count less than 500/mm^3

- Platelet count less than 20,000/mm^3

- Hemoglobin less than 8 g/dL

- Morphologic evidence of MDS with clonal chromosomal abnormalities

- Leukemia transformation

- Other marrow failure syndromes, including any of the following (stratum closed
to accrual):

- Blackfan-Diamond syndrome that is unresponsive to medical therapy

- Kostmann's congenital agranulocytosis unresponsive to medical therapy

- Congenital amegakaryocytic thrombocytopenia

- Thrombocytopenia absent radius

- Combined immune deficiencies including, but not limited to the following:

- Severe combined immunodeficiency (SCID)

- Wiskott-Aldrich syndrome

- Leukocyte adhesion defect

- Chediak-Higashi disease

- X-linked lymphoproliferative disease

- Adenosine deaminase deficiency

- Purine nucleoside phosphorylase deficiency

- X-linked SCID

- Common variable immune deficiency

- Nezeloff's syndrome

- Cartilage hair hypoplasia

- Reticular dysgenesis

- No active CNS leukemia (cerebrospinal fluid with WBC greater than 5/mm^3 and
malignant cells on cytospin)

- No SCID patients who do not require cytoreduction

- No dyskeratosis congenita

- No primary myelofibrosis

- No grade 3 or greater myelofibrosis

- Familial erythrophagocytic lymphohistiocytosis patients must not have any of the

- Abnormal brain MRI

- Neurologic symptoms

- Lymphocytes and monocytes greater than 7/mm^3 in the cerebrospinal fluid

- No available 5/6 or 6/6 HLA-matched related donor



- 55 and under (over 18 closed to accrual)

Performance status

- Karnofsky 70-100% OR

- Lansky 50-100% (patients under 16 years old)

Life expectancy

- Not specified


- See Disease Characteristics


- SGOT less than 5 times upper limit of normal

- Bilirubin less than 2.5 mg/dL


- Creatinine normal for age OR

- Creatinine clearance or glomerular filtration rate greater than 50% of lower limit of


- LVEF greater than 40% at rest and must improve with exercise* OR

- Shortening fraction greater than 26%* NOTE: *If symptomatic


- DLCO greater than 45% of predicted* (corrected for hemoglobin)

- FEV_1 and FEC greater than 45% of predicted (corrected for hemoglobin) OR

- Room air oxygen saturation greater than 85%* NOTE: *If symptomatic


- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No uncontrolled viral, bacterial, or fungal infection

- HIV negative


Biologic therapy

- See Disease Characteristics

- More than 12 months since prior allogeneic stem cell transplantation with
cytoreductive preparative therapy

- More than 6 months since prior autologous stem cell transplantation


- See Biologic therapy

Endocrine therapy

- Not specified


- Not specified


- Not specified


- No prior enrollment on this study

- No continuous life support (e.g., mechanical ventilation) within 1 year after study
transplantation (for patients with inborn errors of metabolism)

Type of Study:


Study Design:

Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Philip L. McCarthy, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Roswell Park Cancer Institute


United States: Food and Drug Administration

Study ID:




Start Date:

January 2003

Completion Date:

September 2005

Related Keywords:

  • Leukemia
  • Lymphoma
  • Myelodysplastic Syndromes
  • Myelodysplastic-Myeloproliferative Diseases
  • refractory anemia with excess blasts in transformation
  • refractory anemia with excess blasts
  • refractory anemia with ringed sideroblasts
  • refractory anemia
  • chronic myelomonocytic leukemia
  • childhood acute myeloid leukemia in remission
  • recurrent childhood acute myeloid leukemia
  • secondary acute myeloid leukemia
  • childhood acute lymphoblastic leukemia in remission
  • recurrent childhood acute lymphoblastic leukemia
  • accelerated phase chronic myelogenous leukemia
  • blastic phase chronic myelogenous leukemia
  • chronic phase chronic myelogenous leukemia
  • acute undifferentiated leukemia
  • recurrent/refractory childhood Hodgkin lymphoma
  • recurrent childhood large cell lymphoma
  • recurrent childhood lymphoblastic lymphoma
  • recurrent childhood small noncleaved cell lymphoma
  • untreated childhood acute lymphoblastic leukemia
  • untreated childhood acute myeloid leukemia and other myeloid malignancies
  • de novo myelodysplastic syndromes
  • previously treated myelodysplastic syndromes
  • secondary myelodysplastic syndromes
  • atypical chronic myeloid leukemia
  • myelodysplastic/myeloproliferative disease, unclassifiable
  • Leukemia
  • Lymphoma
  • Myelodysplastic Syndromes
  • Preleukemia
  • Myeloproliferative Disorders
  • Myelodysplastic-Myeloproliferative Diseases



Roswell Park Cancer Institute Buffalo, New York  14263
Fred Hutchinson Cancer Research Center Seattle, Washington  98109
Jonsson Comprehensive Cancer Center, UCLA Los Angeles, California  90095-1781
Indiana University Cancer Center Indianapolis, Indiana  46202-5265
University of Minnesota Cancer Center Minneapolis, Minnesota  55455
Duke Comprehensive Cancer Center Durham, North Carolina  27710
Ireland Cancer Center Cleveland, Ohio  44106-5065
Medical City Dallas Hospital Dallas, Texas  75230
Vanderbilt-Ingram Cancer Center Nashville, Tennessee  37232-6838
North Shore University Hospital Manhasset, New York  11030
Hackensack University Medical Center Hackensack, New Jersey  07601
Children's Hospital Los Angeles Los Angeles, California  90027-0700
Children's Hospital of Orange County Orange, California  92668
Children's National Medical Center Washington, District of Columbia  20010-2970
Children's Mercy Hospital Kansas City, Missouri  64108
Children's Hospital of Pittsburgh Pittsburgh, Pennsylvania  15213
Children's Hospital of New Orleans New Orleans, Louisiana  70118
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Boston, Massachusetts  02115
Cardinal Glennon Children's Hospital Saint Louis, Missouri  63104
City of Hope Comprehensive Cancer Center Duarte, California  91010
Spectrum Health and DeVos Children's Hospital Grand Rapids, Michigan  49503
James P. Wilmot Cancer Center at University of Rochester Medical Center Rochester, New York  14642
Children's Medical Center of Dallas Dallas, Texas  75235
Texas Transplant Institute San Antonio, Texas  78229
Children's Medical Center, University of California San Francisco San Francisco, California  94143-1278